Treatment of inflammatory bowel disease with corticosteroids

Gastroenterology Clinics of North America

Volumn 33, Issue 2, 2004, Pages 171-189

  Katz, Jeffry A ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AZATHIOPRINE; BECLOMETASONE DIPROPIONATE; BETAMETHASONE; BISPHOSPHONIC ACID DERIVATIVE; BUDESONIDE; CALCIUM; CORTICOSTEROID; CORTICOTROPIN; CORTISONE; CYCLOSPORIN; DEXAMETHASONE; FLUTICASONE; HYDROCORTISONE; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; PLACEBO; PREDNISOLONE; PREDNISOLONE 3 SULFOBENZOATE; PREDNISONE; RISEDRONIC ACID; TIXOCORTOL PIVALATE; VITAMIN D;

ABDOMINAL ABSCESS; ACNE; ADRENAL CORTEX INSUFFICIENCY; ADRENAL HEMORRHAGE; ADRENAL INSUFFICIENCY; ADRENAL SUPPRESSION; AGE; ANAPHYLAXIS; ANGER; ASEPTIC NECROSIS; ATROPHY; BONE NECROSIS; CATARACT; CELL FUNCTION; COGNITIVE DEFECT; CROHN DISEASE; DELIRIUM; DEPRESSION; DEVELOPMENTAL DISORDER; DIABETES MELLITUS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; ECCHYMOSIS; ENTERITIS; FATTY LIVER; FRAGILITY FRACTURE; GENETIC PREDISPOSITION; GLAUCOMA; GROWTH RETARDATION; HALLUCINATION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOKALEMIA; IMMUNOCOMPETENT CELL; INFECTION; INFECTION RISK; INSOMNIA; IRRITABILITY; LYMPHOCYTOPENIA; MANIA; MOOD DISORDER; MOON FACE; MYOPATHY; NEUROPATHY; OSTEOPENIA; OSTEOPOROSIS; PERITONITIS; PREGNANCY; PREMATURITY; PSYCHOSIS; PURPURA; REVIEW; SPONTANEOUS ABORTION; STILLBIRTH; STRIA; TREATMENT OUTCOME; ULCER; ULCERATIVE COLITIS; WEIGHT GAIN; WOUND HEALING IMPAIRMENT;

ADRENAL CORTEX HORMONES; BUDESONIDE; HUMANS; INFLAMMATORY BOWEL DISEASES; RANDOMIZED CONTROLLED TRIALS;

EID: 2942557091     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gtc.2004.02.002     Document Type: Review

References (108)

1. Podolsly D.K. Inflammatory bowel disease. N Engl J Med. 347:2002;417-429
2. Sands B.E. Therapy of inflammatory bowel disease. Gastroenterology. 118:2000;S68-S82
3. Kornbluth A., Sachar D.B. Ulcerative colitis: practice guidelines in adults. Am J Gastroenterol. 92:1997;204-211
4. Hanauer S.B., Sandborn W. Management of Crohn's disease in adults. Am J Gastroenterol. 96:2001;635-643
5. Truelove S.C., Witts L.F. Cortisone in ulcerative colitis: final report on a therapeutic trial. BMJ. 2:1955;1041-1048
6. Baker D.E. Budesonide modified-release capsules. Rev Gastroenterol Disord. 1:2001;147-155
7. Meyers S., Sachar D.B., Goldberg J.D., Janowitz H.D. Corticotropin versus hydrocortisone in the intravenous treatment of ulcerative colitis. Gastroenterology. 85:1983;351-357
8. Truelove S.C., Witts L.J. Cortisone and corticotrophin in ulcerative colitis. BMJ. 1:1959;387-394
9. Simpson W.T. Adrenal hemorrhage during the treatment ulcerative colitis with adrenocorticotropic hormone. Can J Gastroenterol. 22:1979;82-83
10. Gustafsson J.A., Carlstedt-Duke J., Poellinger L., Okret S., Wikstrom A.C., Bronnegard M., et al. Biochemistry, molecular biology, and physiology of the glucocorticoid receptor. Endocr Rev. 8:1987;185-234
11. Andus T., Targan S.R. Glucocorticoids. Targan S.R., Shanahan F. Inflammatory bowel disease: from bench to bedside. 1994;487-502 Williams & Wilkins, Baltimore
12. Distelhorst C.W. Recent insight into the structure and function of the glucocorticoid receptor. J Lab Clin Med. 113:1989;404-412
13. Schleimer R.P. Effects of glucocorticoids on inflammatory cells relevant to their therapeutic applications in asthma. Am Respir Dis. 141:1990;S59-S69
14. Gillis S., Crabtree G.R., Smith K.A. Glucocorticoid-induced inhibition of T-cell growth factor production I. The effect of mitogen-induced lymphocyte proliferation. J Immunol. 123:1979;1624-1631
15. Ross J.S., Bacon K.B., Camp R.D. Potent and selective inhibition of in vitro lymphocyte migration by cyclosporine and dexamethasone. Immunopharmacol Immunotoxical. 12:1990;439-455
16. Werb Z. Biochemical actions of glucocorticoids on macrophages in culture: specific inhibition of elastase, collagenase, and plasminogen activator secretion and effects on other metabolic functions. J Exp Med. 147:1978;1695-1712
17. Fauci A.S. Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med. 84:1976;304-315
18. Williams T.J., Yarwood H. Effect of glucocorticoids on microvascular permeability. Am Rev Respir Dis. 141:1990;S39-S43
19. Dearing W.H., Brown P.W. Experiences with cortisone and ACTH in chronic ulcerative colitis. Proc Staff Meet Mayo Clin. 25:1950;486-488
20. Elliott J.M., Kiefer E.D., Hurxthal L.M. Treatment of chronic ulcerative colitis with pituitary adrenocorticotrophic hormone (ACTH): clinical study of 28 cases. N Engl J Med. 245:1951;288-292
21. Truelove S.C., Witts L.J. Cortisone in ulcerative colitis: preliminary report on a therapeutic trial. BMJ. 2:1954;375-378
22. Lennard-Jones J.E., Longmore A.J., Newell A.C., Wilson C.W.E., Jones F.A. An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment of ulcerative colitis. Gut. 1:1960;217-222
23. Truelove S.C., Jewell D.P. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet. 2:1974;1067-1070
24. Baron J.H., Connell A.M., Kanaghinis T.G., Lennard-Jones J.E., Jones F.A. Out-patient treatment of ulcerative colitis: comparison between three doses of oral prednisone. BMJ. 2:1962;441-443
25. Powell-Tuck J., Brown R., Lennard-Jones J.E. A comparison of oral prednisolone as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol. 13:1987;833-837
26. Hanauer S.B. Medical therapy for ulcerative colitis. Kirsner J.B. Inflammatory bowel disease. 5th edition:2000;529-556 WB Saunders, Philadelphia
27. Katz J.A. Medical and surgical management of severe colitis. Semin Gastrointest Dis. 11:2000;18-32
28. D'Haens G., Lemmens L., Geboes K., Vandeputte L., Acker F.V., Mortelmans L., et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology. 120:2001;1323-1329
29. Kjeldsen J. Treatment of ulcerative colitis with high doses of oral prednisolone. Scand J Gastroenterol. 28:1993;821-826
30. Kristensen M., Koudahl G., Fischerman K., Jarnum S. High dose prednisone treatment in sever ulcerative colitis. Scand J Gastroenterol. 9:1974;177-183
31. Jarnerot G., Rolny P., Sandberg-gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology. 89:1985;1005-1013
32. Truelove S.C., Lee E.G., Willoughby C.P., Kettlewell M.G.W. Further experience in the treatment of severe attacks of ulcerative colitis. Lancet. 2:1978;1086-1088
33. Rosenberg W., Ireland A., Jewell D.P. High-dose methylprednisolone in the treatment of active ulcerative colitis. J Clin Gastroenterol. 12:1990;40-41
34. Lennard-Jones J.E. Toward optimal use of corticosteroids in ulcerative colitis and Crohn's disease. Gut. 24:1983;177-181
35. Travis S.P.L., Farrant J.M., Ricketts C., Nolan D.J., Mortensen N.M., Kettlewell M.G.W., et al. Predicting outcome in severe ulcerative colitis. Gut. 38:1996;905-910
36. Gold D.M., Levine J.J., Winstein T.A., Kessler B., Pettei M.J. Prolonged medical therapy for severe pediatric ulcerative colitis. Am J Gastroenterol. 90:1995;732-735
37. Lennard-Jones J.E., Misiewicz J.J., Connell A.M., Baron J.H., Jones F.A. Prednisone as maintenance treatment for ulcerative colitis in remission. Lancet. 1:1965;188-189
38. Hanauer S.B., Baert F.J. The management of ulcerative colitis. Annu Rev Med. 46:1995;497-505
39. Marshall J.K., Irvine E.J. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut. 40:1997;775-781
40. Lennard-Jones J.E., Baron J.H., Connell A.M., Jones F.A. A double blind controlled trial of prednisolone-21-phosphate suppositories in the treatment of idiopathic proctitis. Gut. 3:1962;207-210
41. Watkinson G. Treatment of ulcerative colitis with topical hydrocortisone hemisuccinate sodium: a controlled trial employing restricted sequential analysis. BMJ. 2:1958;1077-1082
42. Tuck J.P., Jones J.E.L., May C.S., Wilson C.G., Paterson J.W. Plasma prednisolone levels after administration of prednisolone-21-phosphate as a retention enema in ulcerative colitis. BMJ. 1:1976;193-195
43. Farmer R.G., Schumacher O.G. Treatment of ulcerative colitis with hydrocortisone enemas: relationship of hydrocortisone absorption, adrenal suppression, and clinical response. Dis Colon Rectum. 13:1970;355-361
44. Wood E., Wilson C.G., Hardy J.G. The spreading of foam and solution enemas. Int J Pharmacol. 25:1985;191-197
45. Campieri M. New steroids and new salicylates in inflammatory bowel disease: a critical appraisal. Gut. 50:(Suppl 3):2002;43-46
46. Richter F., Scheppach W. Innovations in topical therapy. Baillieres Clin Gastroenterol. 11:1997;97-109
47. Lindgren S., Lofberg R., Bergholm L., Hellblom M., Carling L., Ung K.A., et al. Effect of budesonide enema on remission and relapse rate in distal ulcerative colitis and proctitis. Scand J Gastroenterol. 37:2002;705-710
48. Hanauer S.B., Robinson M., Pruitt R., Lazenby A.J., Persson T., Nilsson L.G., et al. Budesonide enema for the treatment of active distal ulcerative colitis and proctitis: a dose-ranging study. Gastroenterology. 115:1998;525-532
49. Danielsson A., Hellers G., Lyrenas E., Lofberg R., Nilsson A., Olsson O., et al. A controlled randomized trial of budesonide versus prednisolone retention enema in active distal ulcerative colitis. Scand J Gastroenterol. 22:1987;987-992
50. Danielsson A., Lofberg R., Persson T., Salde L., Schioler R., Suhr O., et al. A steroid enema, budesonide, lacking systemic side effects for the treatment of distal ulcerative colitis or proctitis. Scand J Gastroenterol. 27:1992;9-12
51. Lofberg R., Thomsen O.O., Langholz E., Schioler R., Danielsson A., Suhr O., et al. Budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Aliment Pharmacol Ther. 8:1994;623-629
52. The Danish Budesonide Study Group. Budesonide enema in distal ulcerative colitis: a randomized dose-response trial with prednisolone enema as positive control. Scand J Gastroenterol. 26:1991;1225-1230
53. Lofberg R., Danielsson A., Suhr O., Nilsson A., Schioler R., Nyberg A., et al. Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology. 110:1996;1713-1718
54. Greenberg G., Feagan B., Martin F., Sutherland L., Thomson A., Williams C., et al. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Gastroenterology. 110:1996;45-51
55. Keller R., Stoll R., Foerster E.C., Gutsche N., Domschke W. Oral budesonide therapy for steroid-dependent ulcerative colitis: a pilot trial. Aliment Pharmacol Ther. 11:1997;1047-1052
56. Campieri M., Adamo S., Valpianio D., D'Arienzo A., D'Albasio G., Pitzalis M., et al. Oral beclomethasone diproprionate in the treatment of extensive and left sided active ulcerative colitis: a multicentre randomised study. Aliment Pharmacol Ther. 17:2003;1471-1480
57. Rizzello F., Ginchetti P., D'Arienzo A., Manguso F., DiMatteo G., Annese V., et al. Oral beclomethasone diproprionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study. Aliment Pharmacol Ther. 16:2002;1109-1116
58. Faubion W.A., Loftus E.V., Harmsen W.S., Zinmeister A.R., Sandborn W.J. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 121:2001;255-260
59. Hearing S.D., Norman M., Probert C.S.J., Haslam N., Dayan C.M. Predicting therapeutic outcome in severe ulcerative colitis by measuring in vitro steroid sensitivity of proliferating peripheral blood lymphocytes. Gut. 45:1999;382-388
60. Summers R., Switz D., Sessions J., Becktel J., Best W., Kern F., et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology. 77:1979;847-869
61. Malchow H., Ewe K., Brandes J.W., Goebell H., Ehms H., Sommer H., et al. European cooperative Crohn's disease study (ECCDS): results of drug treatment. Gastroenterology. 86:1984;249-266
62. Gross V., Andus T., Ceasar I., Bischoff S.C., Lochs H., Tromm A., et al. Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. German/Austrian Budesonide Study Group. Eur J Gastroenterol Hepatol. 8:1996;905-909
63. Rutgeerts P., Lofberg R., Malchow H., Lamers C., Olaison G., Jewell D., et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med. 331:1994;842-845
64. Jones J.H., Lennard-Jones J.E. Corticosteroids and corticotrophin in the treatment of Crohn's disease. Gut. 7:1966;181-186
65. Bergman L., Krause U. Postoperative treatment with corticosteroids and salazosulphapyridine (Salazopyrin) after radial resection for Crohn's disease. Scand J Gastroenterol. 11:1976;651-656
66. Bello C., Goldstein F., Thornton J.J. Alternate-day prednisone treatment and treatment maintenance in Crohn's disease. Am J Gastroenterol. 86:1991;460-466
67. Tremaine W.J., Hanauer S.B., Katz S., Winston B.D., Levine J.G., Persson T., et al. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States. Am J Gastroenterol. 97:2002;1748-1754
68. Greenberg G., Feagan B., Martin F., Sutherland L., Thomson A., Williams C., et al. Oral budesonide for active Crohn's disease. N Engl J Med. 331:1994;836-841
69. Thomsen O.O., Cortot A., Jewell D., Wright J.P., Winter T., TarveloVeloso F., et al. A comparison of budesonide and mesalamine for active Crohn's disease. N Engl J Med. 339:1998;370-374
70. Bar-Meir S., Chowers Y., Lavy A., Abramovitch D., Sternberg A., Leichtmann G., et al. Budesonide versus prednisolone in the treatment of active Crohn's disease. Gastroenterology. 115:1998;835-840
71. Campieri M., Ferguson A., Doe W., Persson T., Nilsson L. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. Gut. 41:1997;209-214
72. Kane S.V., Schoenfeld P., Sandborn W.J., Tremaine W., Hofer T., Feagan B.G. Systematic review: the effectiveness of budesonide therapy for Crohn's disease. Aliment Pharmacol Ther. 16:2002;1509-1517
73. Lofberg R., Rutgeerts P., Malchow H., Lamers C., Danielsson A., Olaison G., et al. Budesonide prolongs time to relapse in ileal and ileocecal Crohn's disease: a placebo controlled one year study. Gut. 39:1996;82-86
74. Gross V., Andus T., Ecker K.W., Raedler A., Loeschke K., Plauth M., et al. Low dose oral pH modified release budesonide for maintenance of steroid induced remission of Crohn's disease. Gut. 42:1998;493-496
75. Hellers G., Cortot A., Jewell D., Leijonmarck C.E., Lofberg R., Malchow H., et al. Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. Gastroenterology. 116:1999;294-300
76. Munkholm P., Langholz E., Davidsen M., Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut. 35:1994;360-362
77. Kirschner B.S. The medical management of inflammatory bowel disease in children. Kirsner J.B. Inflammatory bowel disease. 5th edition:2000;578-597 WB Saunders, Philadelphia
78. Saha M.T., Ruuska T., Laippala P., Lenko H.L. Growth of prepubertal children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 26:1998;310-314
79. Sadeghi-Nejad A., Senior B. Adrenal function, growth, and insulin in patients treated with corticoids on alternate days. Pediatrics. 43:1969;277-283
80. Sadeghi-Nejad A., Senior B. The treatment of ulcerative colitis in children with alternate-day corticosteroids. Pediatrics. 43:1969;840-845
81. Lundin P.D., Edsbacker S., Bergstrand M., Ejderhamn J., Linanders H., Hogberg L., et al. Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn's disease. Aliment Pharmacol Ther. 17:2003;85-92
82. Levine A., Broide E., Stein M., Bujanover Y., Weizman Z., Dinari G., et al. Evaluation of oral budesonide for treatment of mild and moderate exacerbations of Crohn's disease in children. J Pediatr. 140:2002;75-80
83. Baldassano R., Braegger C.P., Escher J.C., DeWoody K., Hendricks D.F., Keenan G.F., et al. Infliximab (Remicade) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol. 98:2003;717-720
84. Markowitz J., Rosa J., Grancher K., Aiges H., Daum F. Long-term 6-mercaptopurine treatment in adolescents with Crohn's disease. Gastroenterology. 99:1990;1347-1351
85. Beitens I.Z., Bayarrd F., Ances I.G., Kowarski A., Migeon C.J. The transplacental passage of prednisone and prednisolone in pregnancy near term. J Pediatr. 81:1972;936-945
86. Fraser F.C., Sajoo A. Teratogenic potential of corticosteroids in humans. Teratology. 51:1995;45-46
87. Mogadam M., Dobbins W.O., Korelitz B.I., Ahmed S.W. Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterology. 80:1981;72-76
88. Willoughby C.P., Truelove S.C. Ulcerative colitis and pregnancy. Gut. 21:1980;469-474
89. Connell W., Miller A. Treating inflammatory bowel disease during pregnancy: risks and safety of drug therapy. [published erratum appears in Drug Saf 1999;21:456] Drug Saf. 21:1999;311-323
90. Tripathi R.C., Kirschner B.S., Kipp M., Tripathi B.J., Slotwiner D., Borisuth N.S., et al. Corticosteroid treatment for inflammatory bowel disease in pediatric patients increases intraocular pressure. Gastroenterology. 102:1992;2164-2165
91. Allsop J.R., Lee E.C. Factors which influenced postoperative complications in patients with ulcerative colitis or Crohn's disease of the colon on corticosteroids. Gut. 19:1978;729-734
92. Ehrlich H.P., Hunt T.K. Effects of cortisone and vitamin A on wound healing. Ann Surg. 167:1968;324-328
93. Ismail K., Wessely S. Psychiatric complications of corticosteroid therapy. Br J Hosp Med. 53:1995;495-499
94. Patten S.B., Neute C.I. Corticosteroid-induced adverse psychiatric effects: incidence, diagnosis, and management. Drug Saf. 22:2000;111-122
95. Jacob R., Walsh C., Hunter J.O. Road traffic accident as an iatrogenic complication of steroid treatment in Crohn's disease. Am J Gastroenterol. 97:2002;2154-2155
96. Nahon S., Pisante L., Delas N. A successful switch from prednisone to budesonide for neuropsychiatric adverse effects in a patient with ileal Crohn's disease. Am J Gastroenterol. 96:2001;1953-1954
97. Schoon E.J., Nunen A.B.V., Wouters R., Stockbrugger R.W., Russel M. Osteopenia and osteoporosis in Crohn's disease: prevalence in a Dutch population-based cohort. Scand J Gastroenterol. (Suppl 232):2000;43-47
98. Jahnsen J., Falch J.A., Aadland E., Mowinckel P. Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: a population based study. Gut. 40:1997;313-319
99. Bernstein C.N. Risk factors and prevalence of bone disease in inflammatory bowel disease. Williams C.N., Bursey R.F., Gall D.G., et al. Trends in inflammatory bowel disease therapy 1999. 1999;147-162 Kluwer Academic Publishers, Dordrecht
100. Valentine J.F., Sninsky C.A. Prevention and treatment of osteoporosis in patients with inflammatory bowel disease. Am J Gastroenterol. 94:1999;878-883
101. Silvennoinen J.A., Karttunen T.J., Niemela S.E., Manelius J.J., Lehtola J.K. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut. 37:1995;71-76
102. Cino M., Greenberg G.R. Bone mineral density in Crohn's disease: a longitudinal study of budesonide, prednisone, and nonsteroid therapy. Am J Gastroenterol. 97:2002;915-921
103. Loftus E.V., Crowson C.S., Sandborn W.J., Tremaine W.J., O'Fallon W.M., Melton L.J. Long-term fracture risk in Crohn's disease: a population-based study in Olmstead County, Minnesota. Gastroenterology. 123:2002;468-475
104. Bernstein C.N., Blanchard J.F., Leslie W., Wajda A., Yu B.N. The incidence of fracture among patients with inflammatory bowel disease: a population-based cohort study. Ann Intern Med. 133:2000;795-799
105. American College of Rheumatology Ad Hoc Committee on Glucocorticoid Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid induced osteoporosis. Arthritis Rheum. 22:2001;1496-1503
106. Vakil N., Sparberg M. Steroid-related osteonecrosis in inflammatory bowel disease. Gastroenterology. 96:1989;62-67
107. Stuck A., Minder C.E., Frey F.J. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis. 11:1989;954-963
108. Schlaghecke R., Kornely E., Santen R.T., Ridderskamp P. The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone. N Engl J Med. 326:1992;266-267